Compare FN & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FN | PEN |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 13.2B |
| IPO Year | 2007 | 2015 |
| Metric | FN | PEN |
|---|---|---|
| Price | $513.62 | $336.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 17 |
| Target Price | ★ $489.14 | $357.33 |
| AVG Volume (30 Days) | ★ 566.8K | 546.6K |
| Earning Date | 05-04-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 13.21 | ★ 1155.56 |
| EPS | ★ 5.77 | 4.52 |
| Revenue | ★ $3,419,327,000.00 | $1,403,665,000.00 |
| Revenue This Year | $36.90 | $14.20 |
| Revenue Next Year | $18.35 | $13.60 |
| P/E Ratio | $87.44 | ★ $74.31 |
| Revenue Growth | ★ 18.60 | 17.50 |
| 52 Week Low | $148.55 | $221.26 |
| 52 Week High | $632.99 | $362.41 |
| Indicator | FN | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.37 | 43.99 |
| Support Level | $429.50 | $302.19 |
| Resistance Level | $632.99 | $344.07 |
| Average True Range (ATR) | 36.45 | 2.35 |
| MACD | -7.55 | -0.83 |
| Stochastic Oscillator | 18.65 | 21.27 |
Fabrinet provides advance-level optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company offers a broad range of advance optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, complex printed circuit board assembly, advance-level of packaging, integration, final assembly, and testing. The company generates the majority of its revenue from North America and Asia-Pacific, with the rest from Europe.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.